A 2025 meta-analysis in non–small-cell lung cancer (NSCLC) indicates glucocorticoid administration is significantly associated with worse progression-free survival (PFS) and overall survival (OS) for patients on ICIs (A. Mohamed Sikkander, C. Hazarathaiah Yadav, & Narendra Revanuri, Trans.). (2025). World Journal of Applied Medical Sciences, 2(11), 1-3. https://doi.org/10.65336/WJAMS.2025.21101